The European Commission has approved Novo’s Liraglutide (Victoza), for the treatment of Type 2 Diabetes in Adults.
Novo will launch Victoza in Britain, Germany, and Denmark this summer and in other European markets during the remainder of 2009 and in 2010. Victoza is regarded as the most important compound in Novo’s pipeline and a key FDA decision is still pending. Victoza is used once-daily via subcutaneous injection. The drug is a synthetic glucagon-like peptide-1 (GLP-1).